Alnylam Pharmaceuticals

The FDA approved Redemplo (plozasiran), Arrowhead Pharmaceuticals' first commercial drug, for treating familial chylomicronemia syndrome in adults as an adjunct to diet.

Acuitas Therapeutics presented next-generation lipid nanoparticle (LNP) advancements at the 2025 mRNA Health Conference, featuring novel formulations with up to fourfold improved potency in gene editing and vaccine applications.

Vir Biotechnology will present Week 48 endpoint results from the Phase 2 SOLSTICE trial evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta at AASLD 2025.

Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company.

Over 20 pharmaceutical and biotech companies are actively developing more than 20 therapeutic candidates for Huntington's disease at various clinical and preclinical stages.

Moderna has settled patent infringement lawsuits filed by Alnylam Pharmaceuticals over alleged misuse of lipid nanoparticle technology in COVID-19 vaccines.

Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.

Biotech leaders John Maraganore and Clive Meanwell have launched Corsera Health with the ambitious goal of creating a world without cardiovascular disease.

Zilebesiran, developed by Alnylam Pharmaceuticals and Roche, targets angiotensinogen in the renin-angiotensin-aldosterone system and offers biannual dosing for hypertension management.

The U.S. District Court for the District of Delaware entered a final judgment on July 30, 2025, ruling that Pfizer's COVID-19 vaccine did not infringe any of Alnylam's patents covering nanoparticle technology.